澳华内镜扣非亏1年3季 2021上市募7.5亿中信证券保荐

Core Viewpoint - Aohua Endoscopy (688212.SH) reported a significant decline in financial performance for the first three quarters of 2025, with a notable drop in revenue and net profit compared to the previous year [1]. Financial Performance Summary - For the period of January to September 2025, the company achieved operating revenue of 422.63 million yuan, a year-on-year decrease of 15.57% [1][3]. - The net profit attributable to shareholders was -56.09 million yuan, compared to a profit of 37.30 million yuan in the same period last year [1][3]. - The net profit after deducting non-recurring gains and losses was -68.10 million yuan, down from a profit of 1.48 million yuan in the previous year [1][3]. - The net cash flow from operating activities was -98.69 million yuan, worsening from -138 million yuan year-on-year [1][3]. Previous Financial Year Comparison - In 2024, Aohua Endoscopy reported total operating revenue of 750 million yuan, reflecting a year-on-year growth of 10.54% [4]. - The net profit attributable to shareholders for 2024 was 21.01 million yuan, which represented a decline of 63.68% compared to the previous year [4]. - The net profit after excluding non-recurring items was -628.62 million yuan, down from 4.45 million yuan in the previous year [4].